Summit Therapeutics (SMMT) Current Assets (2018 - 2026)

Summit Therapeutics (SMMT) has 9 years of Current Assets data on file, last reported at $720.6 million in Q2 2026.

• Quarterly Current Assets rose 133.02% year-over-year to $720.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $720.6 million (up 133.02% YoY) and the FY2025 annual result came in at $720.3 million, up 69.98% from the prior year.
• Current Assets climbed to $720.6 million in Q2 2026, from $616.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $720.6 million in Q2 2026 to a low of $79.4 million in Q2 2022.
• A 5-year average of $346.3 million and a median of $278.6 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets surged 574.85% — and 2023, when it plunged 71.11%.
• Tracing SMMT's Current Assets over 5 years: stood at $656.7 million in 2022, then sank by 71.11% to $189.7 million in 2023, then surged by 123.36% to $423.8 million in 2024, then surged by 69.98% to $720.3 million in 2025, then rose by 0.04% to $720.6 million in 2026.
• The last three Current Assets figures came in at $720.6 million (Q2 2026), $616.6 million (Q1 2026), and $720.3 million (Q4 2025), per Business Quant data.